이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immunic 관리

관리 기준 확인 3/4

Immunic's CEO는 Daniel Vitt, Apr2019 에 임명되었습니다 의 임기는 5.17 년입니다. 총 연간 보상은 $ 1.21M, 48.3% 로 구성됩니다. 48.3% 급여 및 51.7% 보너스(회사 주식 및 옵션 포함). 는 $ 407.02K 가치에 해당하는 회사 주식의 0.42% 직접 소유합니다. 407.02K. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 4.1 년입니다.

주요 정보

Daniel Vitt

최고 경영자

US$1.2m

총 보상

CEO 급여 비율	48.3%
CEO 임기	5.5yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	3.9yrs

최근 관리 업데이트

Recent updates

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Oct 13

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Jun 27

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

CEO 보상 분석

Daniel Vitt 의 보수는 Immunic 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$95m
Mar 31 2024	n/a	n/a	-US$98m
Dec 31 2023	US$1m	US$585k	-US$94m
Sep 30 2023	n/a	n/a	-US$129m
Jun 30 2023	n/a	n/a	-US$127m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$520k	-US$120m
Sep 30 2022	n/a	n/a	-US$85m
Jun 30 2022	n/a	n/a	-US$83m
Mar 31 2022	n/a	n/a	-US$79m
Dec 31 2021	US$2m	US$399k	-US$93m
Sep 30 2021	n/a	n/a	-US$83m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$70m
Dec 31 2020	US$1m	US$381k	-US$44m
Sep 30 2020	n/a	n/a	-US$41m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$39m
Dec 31 2019	US$2m	US$202k	-US$35m

보상 대 시장: Daniel 의 총 보상 ($USD 1.21M )은 US 시장( $USD 667.49K ).

보상과 수익: Daniel 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Daniel Vitt (56 yo)

5.5yrs

테뉴어

US$1,211,839

보상

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also served as its President until July 12, 2024. He is also managing director of Immunic Research GmbH in Ha...

리더십 팀

이름	위치	테뉴어	보상	소유권
Duane Nash	Executive Chairman	5.8yrs	US$648.93k	0.024% $ 35.0k
Daniel Vitt	CEO & Director	5.5yrs	US$1.21m	0.42% $ 599.2k
Glenn Whaley	Chief Financial Officer	4.5yrs	US$702.21k	0.028% $ 40.6k
Andreas Muehler	Chief Medical Officer	8.2yrs	US$845.29k	0.36% $ 511.6k
Jason Tardio	COO & President	less than a year	데이터 없음	데이터 없음
Hella Kohlhof	Chief Scientific Officer	7.8yrs	데이터 없음	데이터 없음
Jessica Breu	Head of Investor Relations & Communications	no data	데이터 없음	데이터 없음
Inderpal Singh	General Counsel	3.3yrs	데이터 없음	데이터 없음
Patrick Walsh	Chief Business Officer	3yrs	데이터 없음	데이터 없음
Werner Gladdines	Chief Development Officer	less than a year	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: IMUX 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Duane Nash	Executive Chairman	5.8yrs	US$648.93k	0.024% $ 35.0k
Daniel Vitt	CEO & Director	5.5yrs	US$1.21m	0.42% $ 599.2k
Barclay Phillips	Lead Independent Director	4.9yrs	US$99.16k	0.088% $ 126.6k
Tamar Howson	Independent Director	5yrs	US$75.97k	0.088% $ 126.6k
Jorg Neermann	Independent Director	5.5yrs	US$82.95k	0.11% $ 159.0k
Paul Utz	Member of Scientific Medical Advisory Board	3.9yrs	데이터 없음	데이터 없음
Bruce Sands	Member of Scientific Medical Advisory Board	3.9yrs	데이터 없음	데이터 없음
Fred Lublin	Member of Scientific Medical Advisory Board	3.9yrs	데이터 없음	데이터 없음
Richard Rudick	Independent Director	1.5yrs	US$95.70k	0% $ 0
Simona Skerjanec	Director	less than a year	데이터 없음	데이터 없음
Monika Tornsen	Independent Director	2.3yrs	US$79.67k	0.041% $ 58.7k

3.9yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: IMUX 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Immunic 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

Immunic, Inc., Annual General Meeting, Jun 11, 2024

High number of new directors

Independent Director recently bought US$103k worth of stock

High number of new directors

Recent updates

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

Price target decreased by 13% to US$11.90

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts

Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis

New major risk - Share price stability

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023

Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

High number of new directors

Price target decreased by 15% to US$18.00

Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Independent Director recently bought US$103k worth of stock

Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

High number of new directors

Price target decreased to US$21.17

Price target decreased to US$21.17

Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022

Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Price target increased to US$28.75

Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Price target decreased to US$22.40

Immunic GAAP EPS of -$0.72 in-line

Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic, Inc. Announces Executive Changes

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index

Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis

Price target decreased to US$49.43

Executive Chairman recently bought US$50k worth of stock

Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Immunic, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of Its Phase I Clinical Trial of IMU-935

Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer